miRNA Therapeutics Against Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 4134
Special Issue Editor
Interests: roles of microRNAs in carcinogenesis; anti-cancer effect of phytochemicals; anti-cancer effect of fatty acid-analogues
Special Issue Information
Dear Colleagues,
Molecular target drugs against cancer induce tolerance by activating the alternative signal transduction pathways and developing genetic aberrations. MicroRNA (miRNA) is a group of small non-coding RNA that regulates gene expression at the translation step. MicroRNA targets every gene and depresses the growth-related signal pathways by silencing plural key genes involved in the signal pathways and systems. Accumulating evidence shows that dysregulated expression of tumor-suppressor (TS) miRNA contributes to carcinogenesis. The replacement of TS miRNA into cancer cells is a promising therapeutic because of its effect on tumor cell-specific and fewer resulting occurrences of tolerance. We will welcome papers discussing issues from miRNA medicine.
Prof. Dr. Yukihiro Akao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- microRNA
- tumor-suppressor
- signal transduction pathway
- replacement therapy
- drug delivery system
- drug tolerance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
